BioCardia (BCDA) EBITDA Margin (2011 - 2024)
BioCardia's (BCDA) quarterly EBITDA Margin came in at 54966.67% in Q2 2024, down 4693876.0% year-over-year from N/an in Q3 2023, and down 1228.86% quarter-over-quarter from 4136.36% in Q1 2024.
Powered by 
Analysis
BioCardia (BCDA) EBITDA Margin (2011 - 2024) Analysis & Trends
BioCardia (BCDA) has reported EBITDA Margin for 12 consecutive years, with 54966.67% the latest figure, recorded in Q2 2024.
- On a quarterly basis, EBITDA Margin fell 4693876.0% year-over-year to 54966.67% in Q2 2024; TTM through Mar 2025 was 281733.33%, a 27950919.0% decrease from a year earlier, with the FY2024 full-year figure at 13794.83%, down 1135374.0% from the prior year.
- EBITDA Margin was 54966.67% for Q2 2024 at BioCardia, down from 4136.36% in the prior quarter.
- Over five years, EBITDA Margin peaked at 256.26% in Q2 2022 and troughed at 54966.67% in Q2 2024.
- A 5-year average of 8887.88% and a median of 5514.69% in 2022 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin soared 1098781 bps in 2021 and slumped 4693876 bps in 2024, its largest moves.
- Over 5 years, EBITDA Margin stood at 7604.35% in 2020, then soared by 42 bps to 4381.01% in 2021, then surged by 35 bps to 2847.17% in 2022, then tumbled by 463 bps to 16030.77% in 2023, then slumped by 243 bps to 54966.67% in 2024.
- The last three EBITDA Margin figures came in at 54966.67% (Q2 2024), 4136.36% (Q1 2024), and 16030.77% (Q4 2023), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | 49.00% |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | -1,151.84% |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | -52.26% |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | 14.89% |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | -893.73% |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | -25,827.14% |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | 41.18% |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | 3.31% |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 0.56% |
| 10 | BioCardia | 13.06 Mn | 8.94 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | -54,966.67% |
| Mar 31, 2024 | -4,136.36% |
| Dec 31, 2023 | -16,030.77% |
| Sep 30, 2023 | -727.73% |
| Jun 30, 2023 | -8,027.91% |
| Mar 31, 2023 | -5,484.38% |
| Dec 31, 2022 | -2,847.17% |
| Sep 30, 2022 | -1,443.40% |
| Jun 30, 2022 | -256.26% |
| Mar 31, 2022 | -5,545.00% |
| Dec 31, 2021 | -4,381.01% |
| Sep 30, 2021 | -329.84% |
| Jun 30, 2021 | -5,056.52% |
| Mar 31, 2021 | -6,460.87% |
| Dec 31, 2020 | -7,604.35% |
| Sep 30, 2020 | -11,317.65% |
| Jun 30, 2020 | -13,237.04% |
| Mar 31, 2020 | -12,128.95% |
| Dec 31, 2019 | -1,644.19% |
| Sep 30, 2019 | -1,663.40% |